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The aim of the Cochrane Collaboration is to help people make well-informed decisions about health care by
preparing, maintaining and promoting the accessibility of systematic reviews of the effects of health care
interventions. This aim is as relevant now as it was 20 years ago, when the Cochrane Collaboration was established.
Substantial progress has been made toward addressing challenges to achieving the Collaboration’s aim. At the
same time, a huge amount of work remains to be done. Current challenges include improving the quality of
reviews, methodological challenges, meeting the needs of contributors and users and taking on new challenges
while staying focused on the Collaboration’s aim. Radical thinking and substantial change may be needed to
identify and implement pragmatic strategies to ensure that reviews are up-to-date and informative. Methodological
challenges include the development and application of better methods for addressing explanatory factors,
incorporating non-randomized evidence and making comparisons across multiple interventions. Innovations in
editorial processes and strategies to meet the needs of low- and middle-income countries and diverse users of
Cochrane reviews are needed. Finally, although it is important to consider broadening the aims of the Collaboration
to include types of questions other than the effects of interventions and types of products other than the Cochrane
Library, we should not lose sight of the aim of the Cochrane Collaboration. Addressing that aim is still a major
challenge that requires the collaboration of thousands of people around the world and continuing improvements
in the methods used to achieve that aim.Background
At the turn of the 21st century, I described 10 major
challenges to achieving the Cochrane Collaboration’s
aim [1,2]. Herein I consider progress in addressing those
challenges and a new set of challenges. The need to
address these challenges (by the Cochrane Collaboration
or by others) remains the same; that is, that the alterna-
tive––poorly informed decisions––is not acceptable.The Cochrane Collaboration’s aim
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Ethical challenges
1 Building on enthusiasm while avoiding duplication
2 Building on enthusiasm while minimizing bias
3 Promoting access while ensuring continuity
Social challenges
4 Ensuring sustainability
5 Accommodating diversity
Logistical challenges
6 Identifying trials
7 Managing criticisms and updating
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8 Deciding what types of studies to include in reviews
9 Summarizing the strength of evidence
10 Effectively involving consumers
Discussion
Recent critiques of the Cochrane Collaboration have
questioned the relevance of Cochrane reviews; the
sustainability of the approach taken by the Cochrane
Collaboration [3]; whether increasing rigor, demands on
review authors and the cost of Cochrane reviews are
warranted [3,4]; and whether Cochrane reviews are not
rigorous enough [5]. My view is that the aim of the
Cochrane Collaboration is as relevant now as it was
20 years ago. We need methods that are both efficient and
that produce reviews that are reliable and informative. Al-
though we should continue to encourage and welcome
criticism and to question the methods that we use, there
is less reason to question the importance of our aim or the
principles upon which our work is based [1].
Progress since the turn of the 21st century
We have made substantial progress toward addressing
the challenges listed in Box 2. The Cochrane Collabor-
ation continues to generate and build on enthusiasm.
The number of contributors has increased from more
than 4,000 in 1999 to over 40,000 in 2013, including
more than 24,000 review authors. There are now 54
review groups, 9 of which have been registered since
1999. The number of completed Cochrane reviews has
increased from less than 700 (and more than 600 proto-
cols) to over 5,000 (and more than 2,000 protocols).
Review groups continue to struggle to find a balance
between accommodating the specific interests of review
authors while avoiding overlapping reviews and reviews
that are too narrowly or too broadly focused. New innova-
tions that help address this challenge include overviews of
reviews [6], priority-setting processes [7,8], collaborating
with and responding to the needs of stakeholder organiza-
tions [4] and developing and implementing policies that
guide decisions about which new titles to register and for
managing reviews that are within the scope of more than
one review group [9]. New databases such as PDQ-
Evidence (www.pdq-evidence.org) and Epistemonikos
(www.epistemonikos.org) make it possible to quickly and
easily identify related systematic reviews and see where
there are gaps and overlap.
The Cochrane Database of Systematic Reviews (CDSR)
has a high impact factor (5.9 in 2011, the 10th-highest im-
pact factor among 153 journals categorized as Medicine,
General and Internal, based on 7,721 citations of 1,306 re-
views published in 2009 and 2010), and there is increased
access to Cochrane reviews. As a consequence, fewerauthors request to publish duplicate versions of Cochrane
reviews in other journals, and the Collaboration now has a
policy that virtually excludes this. Registration of Cochrane
review titles has been an essential tool to reduce duplication
of Cochrane reviews. More recently, a register of systematic
review protocols for non-Cochrane reviews (PROSPERO)
has been established to help reduce unplanned duplication
of non-Cochrane systematic reviews [10].
Registering protocols can also help to reduce bias in
reviews [7]. Other innovations to address the risk of bias
include developing and implementing a clear policy regard-
ing declarations of interest and commercial sponsorship
[11] and a tool for systematically assessing and reporting
risks of bias in included studies [12]. There have been a
number of initiatives to help ensure that reviews address
questions of global importance and avoid taking a perspec-
tive that is biased toward high-income countries [13-17].
These initiatives have also helped to accommodate diver-
sity by enabling participation in the Collaboration by
people in low- and middle-income countries (LMICs).
Access to the Cochrane Library has increased substan-
tially. Over half of the world’s population now has one-
click access that is free at the point of use, including free
access in all low-income countries. Paid national licenses
have also contributed to continuity and the sustainability
of the Collaboration, among other things, by paying for
methods innovations [18] and an Editorial Unit focused on
improving the quality of the Cochrane Library [19]. This
year, an open access policy was introduced, making all
Cochrane reviews open access 12 months after publication
with an option to pay a publication fee to make a review
open access immediately. This policy and other policies
that increase access to Cochrane reviews will likely further
contribute to ensuring continuity and sustainability by
helping to ensure demand for Cochrane reviews.
Summaries of findings tables and improvements in
plain language summaries help to improve assessments
of the certainty of the evidence summarized in Cochrane
reviews and to communicate the key findings [20-22].
These innovations contribute further to ensuring con-
tinuity and sustainability by improving the accessibility
and quality of Cochrane reviews, provided they are
implemented across reviews. Currently only about 10%
of reviews have a summary of findings table.
Current challenges
Although we have achieved a great deal over the past
20 years and substantial progress has been made toward
achieving the Collaboration’s aims, a huge amount of work
remains to be done. An updated list of challenges includes
improving the quality of reviews, methodological chal-
lenges, meeting the needs of contributors and users and
taking on new challenges while staying focused on the Col-
laboration’s aim.
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Cochrane Collaboration
Improving the quality of reviews
1 Updating reviews
2 Ensuring that reviews are informative
Methodological challenges
3 Addressing explanatory factors*
4 Incorporating evidence from nonrandomized studies
5 Comparing multiple interventions
Meeting the needs of contributors and users
6 Ensuring that editorial processes are effective and
efficient
7 Addressing the needs of low- and middle-income
countries
8 Meeting the needs of diverse users
Taking on new challenges while staying focused on the
Collaboration’s aim
9 Addressing different types of questions
10 Preparing, maintaining and promoting the
accessibility of systematic reviews of the effects of
health care interventions
*Characteristics of people (including their settings or
contexts), interventions, the comparison, outcome mea-
sures, or study design that could potentially explain dif-
ferences in results or limit the applicability of findings.
The challenge of keeping reviews up-to-date has
increased since 1999. There are now many more reviews
and little improvement in the efficiency of updating
strategies. We need to further develop, evaluate and
implement pragmatic strategies to update reviews effect-
ively and efficiently. These include strategies for priori-
tizing which reviews need updating and when [23-25],
more efficient search strategies, automated processes
[26] and ensuring that review groups are adequately
resourced and able to provide support to review authors.
Radical thinking and substantial change may be needed,
such as reducing the number of review groups and
revamping editorial processes to ensure that they are
efficient, support review authors and minimize the
burden placed on authors, referees and editorial teams.
At the same time, there are many ways in which reviews
could be improved and made more informative. The Meth-
odological Expectations of Cochrane Intervention Reviews
(MECIR) include 80 standards for the conduct of reviews
and 108 for the reporting of reviews [27]. Manyshortcomings can be identified in Cochrane reviews using
the MECIR or other standards. Given that many review
authors and editorial teams are already overwhelmed, it is
necessary to set priorities regarding which improvements
are most important and to take a gradual approach toward
improving the reliability, readability and usefulness of
Cochrane reviews. An example of a list of initial improve-
ments that could be made in each new and updated review
is shown below. Such lists may vary to some extent from
review group to review group. They also will change over
time as improvements are made and new priorities arise.
However, the ultimate aim should remain to make
Cochrane reviews as informative and useful as possible.
An initial list of improvements for new and updated
Cochrane reviews
Ensuring that reviews are informative
1. Ensure that any important potential adverse
effects of the interventions are addressed
(whether the included studies report those
outcomes or not).
2. Identify relevant disadvantaged groups and
address differential effects and applicability to those
groups in the Results and Discussion sections of
the review [28].
3. Include summary of findings tables and justifying
assessments of the certainty of the evidence [29].
Include full evidence profiles as appendices.
4. Ensure that the conclusions in the abstract,
discussion and implications for practice are
consistent with the summary of findings.
5. Interpret statistical significance correctly [30].
6. Base conclusions only on findings from the
synthesis of included studies, and do not make
recommendations.
7. Ensuring the methodological quality of reviews
8. Explain and justify any changes to the protocol.
9. Include risk of bias tables.
10. Provide a clear description of factors that affect
interpretation and judgment about the reliability
of any subgroup estimates [25-27]. Ensure that
reviews are readable.
11. Ensure that results are reported consistently in the
abstract, summary of findings and the Results and
Discussion sections.
12. Keep the main text as short as possible; for
example, document in appendices search strategies,
lengthy aspects of the protocol that were not
implemented and other details of the review that
are not of interest to most readers.
13.Make sure the review is understandable to someone
who is not familiar with the topic of the review and
that it is easy to read.
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addressing explanatory factors (in subgroup analyses,
exploring heterogeneity or considering the applicability of
results) [31-33], incorporating non-randomized evidence
and making comparisons across multiple interventions
[34] are needed. Incorporating nonrandomized evidence
in Cochrane reviews may be important for a number of
reasons. On the other hand, including nonrandomized evi-
dence requires additional time, increases the difficulty of
doing a review and may not be informative [35]. Although
several review groups routinely conduct reviews of
nonrandomized studies [36-38], much work is needed to
develop pragmatic strategies for deciding when and how
to incorporate nonrandomized evidence in Cochrane re-
views [35,39-42].
We have taken important steps toward supporting
contributors in LMICs and ensuring the relevance of
Cochrane reviews to people living in LMICs. It is neces-
sary to continue and expand upon those efforts. This
should include strategies for providing ongoing support to
keep up with methodological developments, helping
people whose first language is not English and securing
sustainable sources of funding and protected time to work
on reviews. Working with partners such as the World
Health Organization is one important way of ensuring
reviews meet the needs of people living in LMICs.
Innovations are needed to ensure that the needs of
both contributors and users are met. Innovations that
take advantage of CDSR being an electronic publication
can play an important role in meeting the needs of
diverse users. For example, interactive summary of find-
ings tables would enable review authors to tailor their
summary of findings to different target audiences
(for example, health professionals, patients, policymakers
and guideline developers) and speakers of different
languages and would allow users to interact with the
summaries by expanding or reducing the amount of
information that is shown and accessing explanations
and alternative presentations using numbers, text or
visualizations [43]. Reviews could also incorporate inter-
active tables that address the relevance of the findings of
reviews to different contexts [17,44]. Comments could
be solicited from people from different contexts with
different perspectives that address both the applicability
of the findings and could help to elucidate other factors
(besides the evidence of effects) that need to be consid-
ered when making a decision [45].
Conclusion
Although it is important to consider broadening the aims
of the Collaboration to include other types of questions
(such as reviews of diagnostic test accuracy [46] and quali-
tative evidence of factors affecting the implementation of
health interventions [47]) and other products (such asderivative publications), we should not lose sight of the
original aims of the Cochrane Collaboration: preparing,
maintaining and promoting the accessibility of systematic
reviews of the effects of health care interventions.
Addressing those aims is still a huge challenge that will
continue to require the collaboration of thousands of
people around the world and continuing improvements in
the methods used to achieve those aims.
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